Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Down 90.7% in September

Pasithea Therapeutics Corp. (NASDAQ:KTTA) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 400 shares, a drop of 90.7% from the August 31st total of 4,300 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average trading volume of 17,100 shares, the short-interest ratio is currently 0.0 days.

Pasithea Therapeutics Trading Up 52.1 %

Shares of KTTA traded up $2.00 during mid-day trading on Thursday, reaching $5.85. 56,701,900 shares of the company’s stock were exchanged, compared to its average volume of 330,366. The company has a 50-day simple moving average of $4.73 and a two-hundred day simple moving average of $5.86. Pasithea Therapeutics has a 52-week low of $3.61 and a 52-week high of $17.40.

Pasithea Therapeutics (NASDAQ:KTTA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($3.71) earnings per share for the quarter.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.